These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22762033)

  • 1. Quality of life and physicians' perception in myelodysplastic syndromes.
    Oliva EN; Finelli C; Santini V; Poloni A; Liso V; Cilloni D; Impera S; Terenzi A; Levis A; Cortelezzi A; Ghio R; Musto P; Semenzato G; Clissa C; Lunghi T; Trappolini S; Gaidano V; Salvi F; Reda G; Villani O; Binotto G; Cufari P; Cavalieri E; Spiriti MA
    Am J Blood Res; 2012; 2(2):136-47. PubMed ID: 22762033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing assessment of diabetes-related quality of life between patients and their physicians.
    Tamir O; De-Paz NS; Dvir D; Heymann AD
    Health Qual Life Outcomes; 2018 Nov; 16(1):214. PubMed ID: 30453978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.
    Efficace F; Gaidano G; Breccia M; Voso MT; Cottone F; Angelucci E; Caocci G; Stauder R; Selleslag D; Sprangers M; Platzbecker U; Ricco A; Sanpaolo G; Beyne-Rauzy O; Buccisano F; Palumbo GA; Bowen D; Nguyen K; Niscola P; Vignetti M; Mandelli F
    Lancet Oncol; 2015 Nov; 16(15):1506-1514. PubMed ID: 26404501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin Level.
    Haring Y; Goldschmidt N; Taha S; Stemer G; Filanovsky K; Hellman I; Okasha D; Krayem B; Levi I; Rosenbaum H; Koren-Michowitz M; Yagna S; Nemets A; Gino-Moor S; Saban R; Cohen J; Halperin E; Wolach O; Dally N; Merkel D; Oster HS; Mittelman M;
    J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.
    Oliva EN; Lauseker M; Aloe Spiriti MA; Poloni A; Cortelezzi A; Palumbo GA; Balleari E; Sanpaolo G; Volpe A; Ricco A; Ronco F; Alati C; D'Errigo MG; Santacaterina I; Kündgen A; Germing U; Latagliata R
    Cancer Med; 2015 Dec; 4(12):1789-97. PubMed ID: 26376955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas.
    Brown PD; Ballman KV; Rummans TA; Maurer MJ; Sloan JA; Boeve BF; Gupta L; Tang-Wai DF; Arusell RM; Clark MM; Buckner JC
    J Neurooncol; 2006 Feb; 76(3):283-91. PubMed ID: 16163448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life in myelodysplastic syndromes. A special report from the Myelodysplastic Syndromes Foundation, Inc.
    Heptinstall K;
    Oncology (Williston Park); 2008 Feb; 22(2 Suppl Nurse Ed):13-8; discussion 19. PubMed ID: 18434977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function.
    Castelli R; Deliliers GL; Colombo R; Moreo G; Gallipoli P; Pantaleo G
    Ann Hematol; 2014 Sep; 93(9):1523-9. PubMed ID: 24711171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria.
    Escalante CP; Chisolm S; Song J; Richardson M; Salkeld E; Aoki E; Garcia-Manero G
    Cancer Med; 2019 Feb; 8(2):543-553. PubMed ID: 30632713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey.
    Steensma DP; Heptinstall KV; Johnson VM; Novotny PJ; Sloan JA; Camoriano JK; Niblack J; Bennett JM; Mesa RA
    Leuk Res; 2008 May; 32(5):691-8. PubMed ID: 18054795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.
    Efficace F; Cottone F; Abel G; Niscola P; Gaidano G; Bonnetain F; Anota A; Caocci G; Cronin A; Fianchi L; Breccia M; Stauder R; Platzbecker U; Palumbo GA; Luppi M; Invernizzi R; Bergamaschi M; Borin L; Di Tucci AA; Zhang H; Sprangers M; Vignetti M; Mandelli F
    Cancer; 2018 Mar; 124(6):1251-1259. PubMed ID: 29231969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peri-transfusion quality-of-life assessment for patients with myelodysplastic syndromes.
    Abel GA; Klepin HD; Magnavita ES; Jaung T; Lu W; Shallis RM; Hantel A; Bahl NE; Dellinger-Johnson R; Winer ES; Zeidan AM
    Transfusion; 2021 Oct; 61(10):2830-2836. PubMed ID: 34251040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.
    Efficace F; Gaidano G; Breccia M; Criscuolo M; Cottone F; Caocci G; Bowen D; Lübbert M; Angelucci E; Stauder R; Selleslag D; Platzbecker U; Sanpaolo G; Jonasova A; Buccisano F; Specchia G; Palumbo GA; Niscola P; Wan C; Zhang H; Fenu S; Klimek V; Beyne-Rauzy O; Nguyen K; Mandelli F
    Br J Haematol; 2015 Feb; 168(3):361-70. PubMed ID: 25272332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of transfusion burden and comorbidities on the prognosis of patients with myelodysplastic syndromes.
    Sarici A; Ar MC; Yokus O; Ongoren S; Ayer M; Altindal S; Koker HT; Kuzu OF
    Transfus Apher Sci; 2020 Oct; 59(5):102845. PubMed ID: 32591291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions.
    Nilsson-Ehle H; Birgegård G; Samuelsson J; Antunovic P; Astermark J; Garelius H; Engström LM; Kjeldsen L; Nilsson L; Olsson A; Skov-Holm M; Wallvik J; Gulbrandsen N; Hellström-Lindberg E
    Eur J Haematol; 2011 Sep; 87(3):244-52. PubMed ID: 21623919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes.
    Caocci G; Voso MT; Angelucci E; Stauder R; Cottone F; Abel G; Nguyen K; Platzbecker U; Beyne-Rauzy O; Gaidano G; Invernizzi R; Molica S; Criscuolo M; Breccia M; Lübbert M; Sanpaolo G; Buccisano F; Ricco A; Palumbo GA; Niscola P; Zhang H; Fenu S; La Nasa G; Mandelli F; Efficace F
    Leuk Res; 2015 Aug; 39(8):859-65. PubMed ID: 26120100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-perception of symptoms of anemia and fatigue before and after blood transfusions in patients with myelodysplastic syndromes.
    Ryblom H; Hast R; Hellström-Lindberg E; Winterling J; Johansson E
    Eur J Oncol Nurs; 2015 Apr; 19(2):99-106. PubMed ID: 25488465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for achieving transfusion independence in myelodysplastic syndromes.
    Thomas ML
    Eur J Oncol Nurs; 2007 Apr; 11(2):151-8. PubMed ID: 16935559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.
    Castelli R; Schiavon R; Rossi V; Deliliers GL
    Med Oncol; 2018 Apr; 35(5):76. PubMed ID: 29675620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review.
    Pinchon DJ; Stanworth SJ; Dorée C; Brunskill S; Norfolk DR
    Am J Hematol; 2009 Oct; 84(10):671-7. PubMed ID: 19705430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.